Literature DB >> 1594940

The serological response of the common seal (Phoca vitulina) and the grey seal (Halichoerus grypus) to phocine distemper virus as measured by a canine distemper virus neutralisation test.

H J Cornwell1, S S Anderson, P M Thompson, S J Mayer, H M Ross, P P Pomeroy, R Munro.   

Abstract

The application of a canine distemper virus (CDV) neutralisation test revealed that antibody titres of up to 11,620 were present in the sera of common seals during the epizootic of phocine distemper in British waters. However, during the later stages of the epizootic and afterwards, a surprisingly high proportion of animals were still seronegative. Titres of from 90 to 183 were common in diseased animals and were probably indicative of partial immunosuppression. A few animals with proven phocine distemper had titres of less than 64, this being evidence of a more profound immunosuppression. Recovered animals tended to have moderate to high titres and in some cases these persisted for at least 6.5 months. By contrast, the administration of an inactivated CDV vaccine produced antibody which declined rapidly to very low levels within the same period. Infection also occurred in grey seals in 1988 but without severe mortality. Antibody titres in this species nearly always lay in the range 128-734 and persisted at or around this level for at least 12 months. In both common and grey seals, antibody was transferred by suckling from mother to pup but absorption by the pup seemed to take place more slowly than in domestic mammals.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1594940     DOI: 10.1016/0048-9697(92)90036-r

Source DB:  PubMed          Journal:  Sci Total Environ        ISSN: 0048-9697            Impact factor:   7.963


  1 in total

1.  Trends in Stranding and By-Catch Rates of Gray and Harbor Seals along the Northeastern Coast of the United States: Evidence of Divergence in the Abundance of Two Sympatric Phocid Species?

Authors:  David W Johnston; Jaime Frungillo; Ainsley Smith; Katie Moore; Brian Sharp; Janelle Schuh; Andrew J Read
Journal:  PLoS One       Date:  2015-07-22       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.